A strategic licensing agreement has been reached between Stockholm’s Swedish Orphan Biovitrum (STO: SOBI), also dubbed Sobi, and Massachusetts-based Selecta Biosciences (Nasdaq: SELB).
The firms are partnering around the late-stage asset SEL-212, a gout candidate for which Phase III tests are due to commence later this year.
In recent years, Sobi has been investing to develop a stronger position in immunology, coupled with a substantial US base for expansion and growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze